As EPOR is present in various cancer cells, the use of rHuEPO in cancer patients may be problematic due to potential activation of EPO-EPOR signaling pathways resulting in tumor protection (anti-apoptotic action) or proliferation (mitogenic action). This evidence concerns the gene EPO and neoplasm.